Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2018 February;62(1) > Journal of Neurosurgical Sciences 2018 February;62(1):71-7

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

JOURNAL OF NEUROSURGICAL SCIENCES

A Journal on Neurosurgery


Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,522


eTOC

 

REVIEW  CURRENT TREATMENTS FOR EPENDYMOMAFREEfree


Journal of Neurosurgical Sciences 2018 February;62(1):71-7

DOI: 10.23736/S0390-5616.17.04211-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Adjuvant treatments for ependymomas

Emmett A. SARTOR 1, Patrick Y. WEN 1, 2, 3

1 Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA; 2 Division of Neurology, Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; 3 Harvard Medical School, Boston, MA, USA


PDF  


Ependymomas are rare primary central nervous system tumors occurring in children and young adults. They can be indolent or locally aggressive depending on location, histology, and extent of resection. Treatment involves maximal surgical resection and usually focal radiation therapy, depending on the presence of residual disease and tumor grade. Chemotherapy has been studied for both adults and children but do not have an established role in adjuvant therapy. In both age groups, treatment with mainly cisplatin based regimens can be considered in the setting of residual disease after surgery or for salvage therapy when surgery or further radiation is not indicated. In children, chemotherapy can be considered in very young children to delay radiation or to increase the likelihood of complete resection in second look surgery. Targeted agents such as bevacizumab and lapatinib do not have a role in adjuvant therapy for ependymomas but are being explored for recurrent disease. This review discusses adjuvant therapy in both adult and child populations.


KEY WORDS: Chemotherapy, adjuvant - Ependymoma - Neurology - Medical oncology

top of page

Publication History

Issue published online: December 5, 2017
Article first published online: September 22, 2017
Manuscript accepted: September 18, 2017
Manuscript received: September 14, 2017

Cite this article as

Sartor EA, Wen PY. Adjuvant treatments for ependymomas. J Neurosurg Sci 2018;62:71-7. DOI: 10.23736/S0390-5616.17.04211-4

Corresponding author e-mail

patrick_wen@dfci.harvard.edu